Afanat 20mg tablets

Non-small cell lung cancer (NSCLC)

Undesired symptoms or responses vary from person to person as the human body reacts differently to the Afanat 20 mg Tablet, but they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Afanat 20 mg Tablet are:
Infection
Headache,
Fever
Loss of appetite
Rash
High blood pressure
Dry skin
lack of sleep.
Vomiting
Indigestion
Nausea
Kidney damage diarrhea, or constipation

Afanat 20mg Tablet is taken once a day regularly at the same time each day to increase its effectiveness. It is an oral medication that can be taken with or without food. The capsules should not be chewed, opened, or crushed; they should be swallowed.

Brückl WM, Reck M, Griesinger F, Schäfer H, Kortsik C, Gaska T, Rawluk J, Krüger S, Kokowski K, Budweiser S, Ficker JH, Hoffmann C, Schüler A, Laack E. (2023). Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. Ther Adv Med Oncol.;13.
Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., & Hagiwara, K. (2025). First-line gefitinib for patients with advanced non–non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. Journal of Clinical Oncology, 27(9), 1394-1400.
Kim, Y., Lee, S. H., Ahn, J. S., Ahn, M. J., Park, K., & Sun, J. M. (2025). Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer research and treatment: official journal of Korean Cancer
Association, 51(2), 502-509.
Miura, S., Tanaka, H., Misumi, T., Yoshioka, H., Tokito, T., Fukuhara, T., & Thoracic Oncology Research Group and all ACHILLES investigators. (2025). Pragmatic randomized study of afatinib versus chemotherapy for patients with non–small cell lung cancer with uncommon epidermal growth factor receptor mutations: ACHILLES/TORG1834. Journal of Clinical Oncology, 43(18), 2049-2058.
Schuler, M., Wu, Y. L., Hirsh, V., O’Byrne, K., Yamamoto, N., Mok, T., & Yang, J. C. H. (2024). First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. Journal of Thoracic Oncology, 11(3), 380-390.